[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655889":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":24,"interventions":31,"overallOfficials":36,"centralContacts":41,"locations":49,"responsibleParty":65,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":17,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":17,"enrollmentInfo":81,"targetDuration":17,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":96,"whyStopped":17,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of California, Irvine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Rate of Undetectable Measurable Residual Disease (uMRD) at End of Treatment","Efficacy will be determined by rate of uMRD at EOT for both Epcoritamab and BTKi discontinuation","1 year",[14],{"measure":15,"description":16,"timeFrame":12},"Number of Participants with Complete Remission (CR) by International Workshop on CLL (iwCLL) criteria","CR by iwCLL criteria is defined as meeting all parameters which include lymph nodes, liver and\u002For spleen size, constitutional systems, circulating lymphocyte count, platelet count, hemoglobin, and marrow.",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE",[25],{"label":26,"type":27,"description":28,"interventionNames":29},"Epcoritamab","EXPERIMENTAL","Given IV",[30],"Drug: Epcoritamab",[32],{"type":33,"name":26,"description":34,"armGroupLabels":35,"otherNames":17},"DRUG","Interventional Arm",[26],[37],{"name":38,"affiliation":39,"role":40},"Catherine C Coombs, MD","Chao Family Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":17,"email":46},"Chao Family Comprehensive Cancer Center University of California, Irvine","CONTACT","1-877-827-8839","ucstudy@uci.edu",{"name":48,"role":44,"phone":17,"phoneExt":17,"email":17},"University of California Irvine Medical",[50],{"facility":51,"status":17,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Chao Family Comprehensive Cancer Center, University of California, Irvine","Orange","California","92868","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-117.85311,33.78779,{"lat":61,"lon":60},[64],{"name":38,"role":44,"phone":45,"phoneExt":17,"email":46},{"type":40,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Catherine Coombs","Associate Clinical Professor",[69],{"name":70,"class":71},"Genmab","INDUSTRY","100655889","phase-2-epcoritamab-as-consolidation-therapy-for-high-risk-pts-wcll-on-btki-100655889",false,"NCT07819214","Epcoritamab as Consolidation Therapy for High-Risk Pts w\u002FCLL on BTKI","Epcoritamab as Consolidation Therapy for High-risk Patients With Chronic Lymphocytic Leukemia on Bruton Tyrosine Kinase Inhibitor","Inclusion Criteria:\n\n* Patients with CLL and at least 1 of the following risk factors:\n\n  1. ≥1 prior line of therapy before BTKi\n  2. 17p deletion and\u002For TP53 mutation\n  3. Complex karyotype (≥3 chromosomal abnormalities)\n* Treated with a BTKi for ≥ 6 months\n* Receiving or able to obtain a commercial supply of BTKi\n* Measurable residual disease defined as the presence of CLL cells by conventional flow cytometry\n* ALC ≤10 K\u002FmcL\n* Lymph nodes ≤5 cm in the longest diameter\n* Normal organ function and hematologic parameters\n* ECOG performance status of 0-1\n\nExclusion Criteria:\n\n* Active CNS involvement\n* Active immune-mediated cytopenias\n* Current or prior Richter's transformation\n* Second active malignancy requiring treatment (excluding non-melanamatous skin cancers and cancers requiring hormonal therapies alone such as breast\u002Fprostate cancer)\n* Pregnant or breastfeeding","ALL","18 Years",{"count":82,"type":83},24,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).",[89,90,91,92],"CLL","CLL (Chronic Lymphocytic Leukemia)","Chronic Lymphocytic Leukemia (CLL)","BTKi",[89,94,92,95,26],"Chronic Lymphocytic Leukemia","Bruton Tyrosine Kinase Inhibitor","NOT_YET_RECRUITING","2026-09-08",{"date":99,"type":100},"2026-09-14","ACTUAL",{"date":102,"type":83},"2026-10",{"date":104,"type":83},"2032-10",{"name":5,"class":6},1]